EWM
ALXN

Edge Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Edge Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,095
Closed -$482K – 457
2020
Q4 		$482K Buy
3,095
+188
+6% +$24.2K 0.11% 68
2020
Q3 		$333K Sell
2,907
-250
-8% -$27K 0.08% 83
2020
Q2 		$354K Hold
3,157
– – 0.07% 111
2020
Q1 		$284K Hold
3,157
– – 0.06% 121
2019
Q4 		$341K Buy
3,157
+187
+6% +$20K 0.07% 117
2019
Q3 		$290K Buy
2,970
+1,562
+111% +$176K 0.07% 116
2019
Q2 		$182K Sell
1,408
-60
-4% -$7.73K 0.04% 148
2019
Q1 		$199K Hold
1,468
– – 0.05% 134
2018
Q4 		$143K Sell
1,468
-555
-27% -$65.6K 0.04% 157
2018
Q3 		$281K Sell
2,023
-315
-13% -$39.5K 0.07% 118
2018
Q2 		$290K Buy
2,338
+400
+21% +$46.7K 0.07% 119
2018
Q1 		$216K Sell
1,938
-4,121
-68% -$493K 0.06% 119
2017
Q4 		$727K Sell
6,059
-630
-9% -$76.7K 0.21% 68
2017
Q3 		$935K Sell
6,689
-5,951
-47% -$809K 0.28% 55
2017
Q2 		$1.58M Buy
+12,640
New +$1.47M 0.5% 33
2017
Q1 		– Sell
-160
Closed -$20K – 544
2016
Q4 		$20K Buy
+160
New +$19.6K 0.01% 278
2016
Q2 		– Sell
-452
Closed -$63K – 495
2016
Q1 		$63K Buy
+452
New +$66.4K 0.03% 159

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edge Wealth Management's ALXN Position: Q1 2021 in Review

Edge Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 3,095 shares — an estimated $482K sold.

Edge Wealth Management first reported a position in ALXN in Q1 2016 and held it in 17 quarters. The position peaked at $1.58M in Q2 2017. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Edge Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Edge Wealth Management sold 3,095 Alexion Pharmaceuticals shares in Q1 2021, an estimated $482K.
  • Edge Wealth Management first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 17 quarters.
  • Edge Wealth Management's Alexion Pharmaceuticals position peaked at $1.58M in Q2 2017.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Edge Wealth Management's 13F filing for Q1 2021, filed 9 Apr 2021.